10. Johnson & Johnson
$1.6 million in research payments to teaching hospitals (2018)
Big 100 rank: 2
0.1% of R&D spending ($1,764,000,000)
0.005% of annual revenue ($27 billion)
DePuy Synthes Products: Top teaching hospital payments
The top five payments to teaching hospitals in the U.S. from DePuy Synthes totaled $183,989 and went toward orthopedic device studies.
- $77,710 related to Ortho-Knee, AOX for pre-clinical research in rodents to study dose-dependent effects of Covernox antioxidant on ultra-high molecular weight polyethylene liner wear and osteolysis and osteogenesis induced by liner wear debris;
- $34,000 for a study characterizing advanced total knee arthroplasty designs using weight-bearing and soft tissue interaction assessments;
- $24,093 in three individual payments for the TFN Advanced proximal femoral nailing system for a study to evaluate implant material and characterization.
Biosense Webster: Top teaching hospital payments
The top five payments to teaching hospitals in the U.S. from Biosense Webster totaled $152,725 and went toward cardiac devices and studies.
- $43,211 for a payment associated with pre-clinical research;
- $31,563 in two individual payments related to cardiology devices Pentaray and therapeutic catheters Thermocool and Celsius to study the influence of renal deafferentation/denervation on renal neurotransmission and ventricular electrophysiology;
- $23,194 for pre-clinical research associated with the Carto 3 cardiology system.
Ethicon: Top teaching hospital payments
The top five payments to teaching hospitals in the U.S. from Ethicon totaled $152,533 and went toward endo-mechanical devices.
- $49,392 related to the Linx reflux management system for a post-approval study of the device, which treats gastroesophageal reflux disease (GERD);
- $27,473 associated with the Linx system for a prospective, multicenter study of reflux management with the device;
- $26,621 involving a post-approval study of the Linx system;
- $26,269 related to the Linx system for a prospective, multicenter study of reflux management;
- $22,778 for the Caliber study randomized controlled trial of Linx versus double-dose proton-pump inhibitor therapy for reflux disease.